ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer
Results from the phase 3 CLEAR study, presented at the [...]
Results from the phase 3 CLEAR study, presented at the [...]
Treating non-clear cell renal cell carcinoma (RCC) is challenging because [...]
In this phase 2 clinical trial, a combination of everolimus [...]
A new combination of vorolanib, a tyrosine kinase inhibitor plus [...]
A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
The US Food and Drug Administration (FDA) has approved generic [...]
A recent phase I clinical trial assessed the combination of [...]
We are delighted to announce that the Scottish Medicines Consortium (SMC), [...]
Results from the ENTRATA clinical trial to assess telaglenastat in [...]